Mayne Pharma / Epsolay
MICROENCAPSULATED BENZOYL PEROXIDE CREAM 5%
Benzoyl peroxide is the last thing you would put on rosacea skin. Sealed inside silica microcapsules that release it slowly, it produced 47.4% and 49.2% treatment success with application-site pain in 2% of users. This is the best formulation engineering in the register.
Buy it. The formula, the disclosure and the price all hold up.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
We earn nothing on this link. Do not substitute an over-the-counter 5% benzoyl peroxide for this. The concentration is the same and the delivery is the entire drug.
The verdict
The premise sounds wrong. Benzoyl peroxide is a strong oxidiser, it is the standard cause of the stinging, peeling and redness that makes acne treatment miserable, and rosacea skin is the population least able to absorb that. Putting 5% of it on inflamed rosacea faces once daily ought to be a bad idea.
It works because the drug is not really on the skin. Each particle of benzoyl peroxide is enclosed in a silica shell that releases it gradually, so the concentration reaching the stratum corneum at any moment is a fraction of what a conventional 5% cream delivers. The result is an oxidiser with a tolerability profile that reads like a moisturiser: application-site pain in 2% of subjects, erythema in 2%, against 1% each on vehicle.
The efficacy is the second-best in rosacea in this register. Treatment success at twelve weeks — clear or almost clear with at least a two-grade reduction — reached 47.4% and 49.2% against 20.7% and 28.2% on vehicle, with treatment differences of 26.7 and 21.0 points and confidence intervals excluding zero in both trials. Inflammatory lesions fell 68.2% and 69.4% against 38.3% and 46.0%. Only Soolantra at R-40 does better, and not by much.
The trial population is the other reason to take this seriously here: 733 subjects with a mean age of 51, range 18 to 85, 73% female. Along with Finacea Foam at R-42, that makes two rosacea programmes in this register run in the population that actually has the disease. The objection is price — around $563 cash against an average retail near $789 — and the label's own admission that the mechanism in rosacea is unknown.
- Second-best rosacea efficacy in this register: 47.4% and 49.2% treatment success.
- Inflammatory lesions down 68.2% and 69.4% against 38.3% and 46.0% on vehicle.
- Confidence intervals published on every treatment difference.
- Application-site pain in 2% and erythema in 2% — for a 5% oxidiser on rosacea skin.
- Trial population mean age 51, range 18 to 85 — the disease's actual population.
- Co-primary endpoints prespecified and both met in both trials.
- Separation from vehicle from week four.
- Silica microencapsulation is a genuine delivery innovation, not a reformulation.
- Airless 30 g pump, correct packaging for an oxidiser.
- States plainly that the mechanism and pharmacodynamics in rosacea are unknown.
- Both trials carry registration numbers.
- Around $563 to $789 for a 30 g pump, with no generic.
- Trials ran twelve weeks on a lifelong relapsing condition.
- 93% of subjects were Caucasian.
- The label concedes the mechanism of action in rosacea is unknown.
- No stated duration, review point or stopping guidance.
- No head-to-head against ivermectin or azelaic acid, the incumbents.
- Benzoyl peroxide bleaches fabric — towels, pillowcases, collars.
- The obvious cheap substitute, over-the-counter 5% benzoyl peroxide, is not the same product and will not behave the same way.
Every active, assessed
- Benzoyl peroxide5% — microencapsulated
Oxidising agent with bactericidal and keratolytic effects; the precise mechanism in rosacea is stated on the label as unknown
- BENCHMARK
- 2.5% to 10% in conventional acne products
- ASSESSMENT
- An ordinary concentration of an ordinary molecule, made usable on the least tolerant skin in dermatology by enclosing it in silica shells that meter its release. The concentration on the carton tells you almost nothing about what reaches the skin, which is the point — this is the register's strongest single argument that a percentage without a delivery system is not a specification.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| Benzoyl peroxideOxidising agent with bactericidal and keratolytic effects; the precise mechanism in rosacea is stated on the label as unknown | 5% — microencapsulated | 2.5% to 10% in conventional acne products | An ordinary concentration of an ordinary molecule, made usable on the least tolerant skin in dermatology by enclosing it in silica shells that meter its release. The concentration on the carton tells you almost nothing about what reaches the skin, which is the point — this is the register's strongest single argument that a percentage without a delivery system is not a specification. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%84/100
Two multicentre randomised vehicle-controlled trials in 733 subjects with prespecified co-primary endpoints, both met in both trials, confidence intervals on every difference, separation from vehicle from week four, and a trial population with a mean age of 51. Marked down only because twelve weeks is short for a lifelong condition and the label concedes the mechanism is unknown.
- FORMULATION INTEGRITYWEIGHT 20%90/100
The best formulation work in this register. Silica microencapsulation converts the standard cause of topical intolerance into a product with 2% application-site pain, on the population least able to tolerate it. Shipped in an airless 30 g pump, correct for an oxidiser. Fill weight and excipients published. Nothing here is decorative — the delivery system is the therapy.
- DISCLOSUREWEIGHT 15%88/100
Concentration in per cent and milligrams per gram, fill weight, packaging named, both trials with registration numbers, co-primary endpoints with confidence intervals, adverse reactions against vehicle, full trial demographics including mean age and range, and an explicit statement that both the mechanism and the pharmacodynamics in rosacea are unknown. Held back because nothing addresses duration or stopping.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed by us, and the label's figures are extraordinary for the molecule: application-site pain 2%, erythema 2%, both against 1% on vehicle. A panel would establish whether that holds outside a trial, and whether it holds against the over-the-counter product people will inevitably try to substitute.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Benzoyl peroxide bleaches fabric regardless of encapsulation, which is a practical daily consideration a panel should record.
- COST PER APPLICATIONWEIGHT 10%40/100
Around $563 cash against an average retail near $789 for a 30 g pump, with no generic — the encapsulation is patented and there is no way to buy the same thing cheaper. The fill weight is published so cost per gram is computable, and it is high for a molecule available over the counter for a few dollars. That comparison is misleading, and it is the one every buyer will make.
What it is
Benzoyl peroxide 5%, enclosed in silica microcapsules, in a cream applied once daily and approved for the inflammatory lesions of rosacea in adults. A 30 g airless pump, around $563 cash. There is no generic, because the capsule is the invention.
Why this should not work
Benzoyl peroxide is the reason a great many people abandon acne treatment. It oxidises, it strips, it stings, and it produces exactly the erythema and scaling that rosacea patients are already trying to get rid of. Every clinical instinct says keep it away from this population.
Each particle of benzoyl peroxide sits inside a shell of silica. The shell meters the release, so the amount of free oxidiser at the skin surface at any given moment is a fraction of what a conventional 5% cream delivers — while the total dose over the day is enough to do the work. The number on the carton is unchanged. What reaches the skin is not. This is the most complete demonstration in the register that a concentration without a delivery system is not a specification, and it is worth setting beside R-51, where the same argument runs the other way: an unmitigated vehicle turning a good molecule into a 10-to-30% irritation rate.
What the tolerability data say
Epsolay N=488, vehicle N=234. For 5% benzoyl peroxide applied daily to moderate-to-severe papulopustular rosacea, these rates are the finding. A conventional benzoyl peroxide product on the same population would not produce a table that looks like this.
And the efficacy
Success required clear or almost clear with at least a two-grade reduction. Trial 1 (NCT03448939): N=243 against 118. Trial 2 (NCT03564119): N=250 against 122. Differences of 26.7 points (95% CI 16.7–36.8) and 21.0 points (95% CI 10.7–31.3).
Inflammatory lesions fell 68.2% and 69.4% against 38.3% and 46.0% on vehicle, from a mean baseline count of 27.5. Set against R-40, where ivermectin produced reductions of 64.9% and 65.7% and success rates of 38.4% and 40.1%, these are comparable-to-better numbers from a molecule nobody expected to be usable here.
The honest gaps
- The mechanism of action in rosacea is unknown, and the label says so twice — once under mechanism and once under pharmacodynamics.
- Twelve weeks, on a condition managed for decades. No long-term cohort is published, unlike Soolantra's 519 subjects at a year.
- 93% of subjects were Caucasian, the familiar limitation across every rosacea programme in this register.
- No head-to-head against ivermectin or azelaic acid, so the sequencing question is unanswered.
- Nothing on duration or stopping.
- It bleaches fabric, which no amount of encapsulation changes.
If you are considering it
- Try azelaic acid at R-42 first if you are paying cash. It costs a fraction as much and works on the same lesions.
- Do not substitute an over-the-counter 5% benzoyl peroxide. Same number, different product, and the difference is the whole point.
- Once daily, a thin layer, on the whole affected area.
- Give it twelve weeks, but expect movement by week four — that is when both trials separated.
- White pillowcases and towels. It bleaches.
- Check coverage — the spread between cash and covered price here is large.
- Ask what the plan is after twelve weeks, because the label does not say.
- Do the trigger work and wear sunscreen. No rosacea topical substitutes for either.
Where we stand
At 81 this ties with R-42 and sits just under R-40, and it gets there on formulation rather than novelty. The molecule is ancient and available over the counter. What is new is a silica shell that changes what the skin experiences without changing what the carton says.
That is worth stating plainly for a readership constantly being sold concentrations. Two products in this register contain 5% benzoyl peroxide-equivalent chemistry and one of them is unusable on rosacea skin. Two contain tazarotene and one of them irritates six times as many people. The number on the front is the least informative thing on the package.
The strongest rosacea evidence base, with year-scale safety data this lacks.
Comparable lesions, a fraction of the price.
The same argument running the other way — a good molecule in an unmitigated vehicle.
Why the number on the carton is the least informative thing on it.
Who this is for
- Someone with papulopustular rosacea who has not responded adequately to ivermectin or azelaic acid.
- Someone who has tried conventional benzoyl peroxide and found it intolerable — this is a different delivery of the same molecule.
- Someone with insurance coverage, which is what makes the price reasonable.
- Someone in their forties or fifties who wants evidence generated in their own age group.
- Your rosacea is mainly redness and visible vessels — this treats papules and pustules.
- You are paying cash and have not yet tried azelaic acid at R-42, which costs a fraction as much.
- You would substitute an over-the-counter benzoyl peroxide to save money, because that is a different product.
- You cannot live with fabric bleaching.
- You want a mechanism the manufacturer can explain, which this label says it cannot.
We earn nothing on this link. Do not substitute an over-the-counter 5% benzoyl peroxide for this. The concentration is the same and the delivery is the entire drug.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01FDA-approved labelling — EPSOLAY (benzoyl peroxide) cream, 5%, Mayne Pharma Commercial LLC The 5% strength stated as 50 mg per gram in a 30 g airless pump; the two 12-week vehicle-controlled trials (NCT03448939, NCT03564119) in 733 subjects with IGA treatment success of 47.4% against 20.7% and 49.2% against 28.2% and confidence intervals on both differences; inflammatory lesion reductions of 68.2% and 69.4% against 38.3% and 46.0% from a mean baseline of 27.5; the demographic composition of 93% Caucasian, 73% female, mean age 51 with a range of 18 to 85; the adverse reaction table showing application-site pain and erythema at 2% against 1% on vehicle; and the statements that the mechanism of action and the pharmacodynamics in rosacea are unknown. Read 2 August 2026.
- S-02GoodRx — Epsolay pricing A cash price as low as $563.32 against an average retail price near $788.50. Retrieved 2 August 2026.